Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
IIPR Innovative Industrial Properties Inc
NVCN Neovasc Inc
CDE Coeur Mining Inc
BRID Bridgford Foods Corp
SOR Source Capital Inc
RCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026
FAST Fastenal Co
UKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025
KMI Kinder Morgan Inc

Based in Canada
Company profile

Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc., Cybin US Holdings Inc., Adelia Therapeutics Inc. and Cybin IRL Limited.


Last Trade
0.00 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.0009 (-0.15%)
B/A Size
Day's High
Day's Low

10-day average volume:
Latest Earnings Consensus (Q4 ending 03/2022)Next Earnings Announcement
Announced June 22, 2022
--Q4 Consensus
of 5 analysts
-$0.08Difference from
Q1 Earnings
will announce
(Unconfirmed) August 31, 2022

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



CYBN's fiscal year ends in March

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.